S0820, Adenoma and Second Primary Prevention Trial

The investigators hypothesize that the combination of eflornithine and sulindac will be
effective in reducing a three-year event rate of adenomas and second primary colorectal
cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

Intervention

Eflornithine placebo & sulindac, Eflornithine placebo & sulindac placebo, Eflornithine plus sulindac, eflornithine & sulindac placebo

Condition

Colorectal Neoplasms

Investigators

Jason A. Zell, D.O., MPH, Philip J. Stella, David M. King, Shaker R. Dakhil, John A. Ellerton, Deborah W. Wilbur, Amitpal S. Johal, Carl J. Minniti, Michal G. Rose, Matthew L. Ryan, Jay W. Carlson, Chung-Tsen Hsueh, Bret E. Friday, James E. Radford, Sukeshi P. Arora, Shailja Roy, Howard A. Zaren, Donald J. Jurgens, David A. Mullins, Burke J. Brooks, Donald B. Wender, Sagila George, Robert J. Behrens, Arvinder S. Bir, Gamini S. Soori, Bryan A. Faller, Mark F. Kozloff, Mitchell Haut, Richard L. Deming, Uzair B. Chaudhary, Ari D. Baron, Chady A. Leon, Anthony F. Shields, Akm Mosharraf Hossain, Harish G. Ahuja, Isoken Koko, Sunitha Vemulapalli, Jason A. Zell, Bernard M. Evers, Sarah M. Popek, Nina Beri, Britt H. Olmsted, Nagesh H. Jayaram, Mustapha A. Khalife, Martin D. McCarter, Ryan T. Oleszewski, Vincent P. Vinciguerra, Gary E. Goodman, Lisa Bailey, Mark E. Reeves, Steven R. Schuster, Jeffrey L. Berenberg, Nibal Saad, Anwaar Saeed, Aqeel A. Gillani, Devena E. Alston-Johnson, Jennifer A. Dorth, Timothy D. Moore, Powel H. Brown, Jennifer Slim, Bruce S. Lin

See list of participating sites